Minerva Neurosciences (NERV) Reaches $8.02 After 5.00% Up Move, Profile of 17 Analysts Covering U.S. Silica Holdings (SLCA)

June 29, 2017 - By Richard Conner

Among 21 analysts covering U.S. Silica (NYSE:SLCA), 17 have Buy rating, 1 Sell and 3 Hold. Therefore 81% are positive. U.S. Silica had 56 analyst reports since July 30, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Wednesday, April 12 by Jefferies. The rating was upgraded by Jefferies to “Hold” on Friday, February 26. The firm has “Buy” rating by DA Davidson given on Monday, December 7. The stock has “Buy” rating by SunTrust on Wednesday, January 18. As per Wednesday, February 24, the company rating was maintained by RBC Capital Markets. The rating was maintained by Cowen & Co with “Outperform” on Friday, December 2. RBC Capital Markets maintained the stock with “Sector Perform” rating in Thursday, October 29 report. On Thursday, February 25 the stock rating was downgraded by Ladenburg Thalmann to “Neutral”. The stock of U.S. Silica Holdings Inc (NYSE:SLCA) earned “Sector Perform” rating by RBC Capital Markets on Friday, September 18. The firm has “Underperform” rating given on Friday, September 11 by Jefferies. See U.S. Silica Holdings Inc (NYSE:SLCA) latest ratings:

15/06/2017 Broker: Janney Capital Rating: Buy New Target: $51 Initiates Coverage On
30/05/2017 Broker: Jefferies Rating: Buy New Target: $65.0000 Maintain
29/05/2017 Broker: RBC Capital Markets Rating: Buy New Target: $60.00 Maintain
26/05/2017 Broker: RBC Capital Markets Rating: Buy New Target: $60.0000 Maintain
26/05/2017 Broker: Evercore Rating: Outperform New Target: $48 Initiates Coverage On
24/04/2017 Broker: Barclays Capital Old Rating: Overweight New Rating: Equal Weight Old Target: $56.00 New Target: $45.00 Downgrade
12/04/2017 Broker: Jefferies Rating: Buy New Target: $70.00 Maintain
12/04/2017 Broker: Simmons & Co Rating: Overweight Old Target: $63.50 New Target: $64.50 Target Up
18/01/2017 Broker: Suntrust Robinson Rating: Buy Initiate
18/01/2017 Broker: SunTrust Rating: Buy Initiate

The stock of Minerva Neurosciences Inc (NASDAQ:NERV) is a huge mover today! About 690,473 shares traded or 108.76% up from the average. Minerva Neurosciences Inc (NASDAQ:NERV) has risen 56.56% since June 29, 2016 and is uptrending. It has outperformed by 39.86% the S&P500.The move comes after 6 months positive chart setup for the $272.29M company. It was reported on Jun, 29 by Barchart.com. We have $8.42 PT which if reached, will make NASDAQ:NERV worth $13.61M more.

About 166,814 shares traded. U.S. Silica Holdings Inc (NYSE:SLCA) has risen 57.03% since June 29, 2016 and is uptrending. It has outperformed by 40.33% the S&P500.

U.S. Silica Holdings, Inc. is a domestic producer of commercial silica, a specialized mineral that is an input into a range of end markets. The company has market cap of $3.03 billion. The Firm operates in two divisions: Oil & Gas Proppants, and Industrial & Specialty Products. It currently has negative earnings. In the Oil & Gas Proppants segment, it serves the gas and oil recovery market providing fracturing sand, or frac sand, which is pumped down oil and natural gas wells to prop open rock fissures and manage the flow rate of natural gas and oil from the wells.

Among 2 analysts covering Minerva Neurosciences (NASDAQ:NERV), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Minerva Neurosciences had 3 analyst reports since March 9, 2016 according to SRatingsIntel. As per Thursday, May 12, the company rating was reinitiated by Jefferies. JMP Securities maintained it with “Market Outperform” rating and $10 target in Wednesday, March 9 report. The stock of Minerva Neurosciences Inc (NASDAQ:NERV) earned “Buy” rating by Jefferies on Friday, May 27.

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $272.29 million. The Firm is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. It currently has negative earnings. The Company’s product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson’s disease.